Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia in the EU ...

"This is the last chapter — if I get another 30, what do I want to do? My mother made it to 97," the actor said.

The results were so strong in showing the benefit of this therapy for patient survival that we were able to stop the trial ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...